Fluorine-18 prostate-specific membrane antigen (PSMA)-1007 PET/CT was superior to multiparametric MRI for primary locoregional staging of prostate cancer, according to results from a phase II ...
Fluorine-18 prostate-specific membrane antigen (PSMA)-1007 PET/CT improves locoregional staging compared with MRI in patients undergoing surgery for intermediate and high-risk prostate cancer. PSMA ...
Pretreatment 18F-PSMA-1007 PSMA PET/CT more accurately identifies prostate tumors compared with mpMRI. Fluorine-18 prostate-specific membrane antigen-1007 positron emission tomography/computed ...
Among patients with prostate cancer who received MRI-guided stereotactic body radiation therapy (SABR), more than 80% demonstrated “classic” neurovascular bundle patterns and over 96% showed more than ...
Vinblastine Versus Vinblastine Plus Oral Estramustine Phosphate for Patients With Hormone-Refractory Prostate Cancer: A Hoosier Oncology Group and Fox Chase Network Phase III Trial PURPOSE: ...
Magnetic resonance imaging (MRI) constitutes an integral role in contemporary oncology practice. This review was aimed at discussing radiotherapy (RT)–related applications of MRI in the context of ...
Screening for prostate cancer is burdened by a high rate of overdiagnosis. The most appropriate algorithm for population-based screening is unknown. We invited 37,887 men who were 50 to 60 years of ...
Nearly 67% of men with MRI-detected lesions and more than half of those with clinically significant prostate cancer had a PSA level less than 3 ng/mL, investigators reported. Using magnetic resonance ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results